source
- Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for DuchenneRegenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…
- Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypesIbrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…